BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22574157)

  • 1. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA.
    Peng L; Oberst MD; Huang J; Brohawn P; Morehouse C; Lekstrom K; Baeuerle PA; Wu H; Yao Y; Coats SR; Dall'Acqua W; Damschroder M; Hammond SA
    PLoS One; 2012; 7(5):e36412. PubMed ID: 22574157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody.
    Osada T; Hsu D; Hammond S; Hobeika A; Devi G; Clay TM; Lyerly HK; Morse MA
    Br J Cancer; 2010 Jan; 102(1):124-33. PubMed ID: 19953093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reference of the GOLD classification of monoclonal antibodies against carcinoembryonic antigen to the domain structure of the carcinoembryonic antigen molecule.
    Murakami M; Kuroki M; Arakawa F; Kuwahara M; Oikawa S; Nakazato H; Matsuoka Y
    Hybridoma; 1995 Feb; 14(1):19-28. PubMed ID: 7768530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
    Osada T; Patel SP; Hammond SA; Osada K; Morse MA; Lyerly HK
    Cancer Immunol Immunother; 2015 Jun; 64(6):677-88. PubMed ID: 25742933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen.
    Stewart LM; Young S; Watson G; Mather SJ; Bates PA; Band HA; Wilkinson RW; Ross EL; Snary D
    Cancer Immunol Immunother; 1999 Feb; 47(6):299-306. PubMed ID: 10203059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
    Bluemel C; Hausmann S; Fluhr P; Sriskandarajah M; Stallcup WB; Baeuerle PA; Kufer P
    Cancer Immunol Immunother; 2010 Aug; 59(8):1197-209. PubMed ID: 20309546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
    Pishvaian M; Morse MA; McDevitt J; Norton JD; Ren S; Robbie GJ; Ryan PC; Soukharev S; Bao H; Denlinger CS
    Clin Colorectal Cancer; 2016 Dec; 15(4):345-351. PubMed ID: 27591895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
    Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
    Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers.
    Teijeira A; Migueliz I; Garasa S; Karanikas V; Luri C; Cirella A; Olivera I; Cañamero M; Alvarez M; Ochoa MC; Rouzaut A; Rodriguez-Ruiz ME; Sanmamed MF; Klein C; Umaña P; Ponz M; Bacac M; Melero I
    Theranostics; 2022; 12(3):1373-1387. PubMed ID: 35154495
    [No Abstract]   [Full Text] [Related]  

  • 13. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Moek KL; Waaijer SJH; Kok IC; Suurs FV; Brouwers AH; Menke-van der Houven van Oordt CW; Wind TT; Gietema JA; Schröder CP; Mahesh SVK; Jorritsma-Smit A; Lub-de Hooge MN; Fehrmann RSN; de Groot DJA; de Vries EGE
    Clin Cancer Res; 2019 Jun; 25(12):3517-3527. PubMed ID: 30745297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
    Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
    Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel protein isoforms of carcinoembryonic antigen are secreted from pancreatic, gastric and colorectal cancer cells.
    Hatakeyama K; Wakabayashi-Nakao K; Ohshima K; Sakura N; Yamaguchi K; Mochizuki T
    BMC Res Notes; 2013 Sep; 6():381. PubMed ID: 24070190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes.
    Kuwahara M; Kuroki M; Arakawa F; Senba T; Matsuoka Y; Hideshima T; Yamashita Y; Kanda H
    Anticancer Res; 1996; 16(5A):2661-7. PubMed ID: 8917366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic and affinity constants of epitope specific anti-carcinoembryonic antigen (CEA) monoclonal antibodies for CEA and engineered CEA domain constructs.
    Hefta LJ; Neumaier M; Shively JE
    Immunotechnology; 1998 Jun; 4(1):49-57. PubMed ID: 9661814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
    Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
    J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of carcinoembryonic antigen and its predicted immunoglobulin-like domains in HeLa cells for epitope analysis.
    Hefta LJ; Chen FS; Ronk M; Sauter SL; Sarin V; Oikawa S; Nakazato H; Hefta S; Shively JE
    Cancer Res; 1992 Oct; 52(20):5647-55. PubMed ID: 1382844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.